Vascular graft bypass

Information

  • Patent Grant
  • 6605113
  • Patent Number
    6,605,113
  • Date Filed
    Tuesday, April 10, 2001
    23 years ago
  • Date Issued
    Tuesday, August 12, 2003
    21 years ago
  • Inventors
  • Original Assignees
  • Examiners
    • Prebilic; Paul B.
    Agents
    • Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Abstract
Improved methods of treatment of diseased or occluded vascular grafts in patients having undergone coronary artery bypass or other bypass surgery are disclosed. Deployment of a conduit in the myocardium at a site distal to the site of attachment of the coronary artery bypass graft allows oxygenated blood to flow from a chamber in the heart directly into the coronary artery, bypassing blockages in the coronary artery and the graft originally used to bypass the coronary artery. To ensure proper positioning, the conduit is delivered through the graft to the myocardium. A new lining for the existing vein graft and methods of delivery are also disclosed.
Description




BACKGROUND OF THE INVENTION




1. Field of the Invention




This invention relates to an improved treatment of diseased or occluded vascular grafts in patients having undergone coronary artery bypass surgery.




2. Description of the Related Art




Coronary artery disease is a major problem in the U.S. and throughout the world. Coronary arteries as well as other blood vessels frequently become clogged with plaque, which at the very least impairs the efficiency of the heart's pumping action, and can lead to heart attack and death. In some cases, these arteries can be unblocked through noninvasive techniques such as balloon angioplasty. In more difficult cases, a bypass of the blocked vessel is necessary.




In a bypass operation, one or more venous segments are inserted between the aorta and the coronary artery. The inserted venous segments or transplants act as a bypass of the blocked portion of the coronary artery and thus provide for a free or unobstructed flow of blood to the heart. More than 500,000 bypass procedures are performed in the U.S. every year.




Such coronary artery bypass surgery, however, is a very intrusive procedure that is expensive, time-consuming and traumatic to the patient. The operation requires an incision through the patient's sternum (sternotomy), and that the patient be placed on a bypass pump so that the heart can be operated on while not beating. A saphenous vein graft is harvested from the patient's leg, another highly invasive procedure, and a delicate surgical procedure is required to piece the bypass graft to the coronary artery (anastomosis). Hospital stays subsequent to the surgery and convalescence are prolonged.




Over time, the vein graft itself may become diseased, stenosed, or occluded, similar to the original bypassed vessel. Old, diffusely diseased saphenous vein grafts are considered contraindications for angioplasty and atherectomy, severely limiting the options for minimally invasive treatment. Some diseased or occluded saphenous vein grafts are associated with acute ischemic syndromes, however, necessitating some form of intervention.




Thus, there is a need for an improved treatment of diseased or occluded grafts in patients having had coronary bypass surgery.




SUMMARY OF THE INVENTION




The preferred embodiments of the present invention address the need in the previous technology by providing a bypass system that restores the flow of oxygenated blood through the body. In a preferred embodiment, there is provided a method for bypassing an existing coronary artery bypass graft in a patient. A hollow conduit is inserted in the patient's myocardium at a location distal to the site of attachment of the graft, such that the conduit allows oxygenated blood to flow from the patient's heart directly into the coronary artery. The conduit is preferably delivered to the myocardium through the coronary artery bypass graft, to ensure that the conduit is positioned in the myocardium at a site that is distal to both the blockage in the coronary artery, and the site of attachment of the graft to the coronary artery. Locating the proper site, for example, through the left ventricle of the heart is very difficult. Thus, delivery of the conduit through the graft simultaneously solves both the problem of therapy and the problem of locating the proper site for insertion of the conduit in bypass patients.




The methods disclosed herein are preferably performed percutaneously, but other minimally invasive methods, and open-chest methods, can also be used. Prior to insertion into the patient, the conduit is preferably mounted on the distal end of a delivery catheter. The catheter is then inserted into the patient's vasculature, into the aorta, and then into the bypass graft for delivery into the myocardium.




Another embodiment of the invention includes a method for improving the patency of a coronary artery or other arterial or venous bypass graft. A lining is inserted in the hollow interior of the graft and preferably permanently attached to the graft. The lining can be made of various biocompatible materials, but a section of vein from the patient is preferred. The lining can be mounted on an inflatable balloon catheter, such as those used in angioplasty. The distal end of the catheter is delivered to the interior of the graft, and the balloon is inflated to expand the lumen of the graft and the lining. If desired, a delivery catheter can be used to deliver the catheter bearing the lining to the site of the graft. This method improves the “proximal flow” through the existing graft.




The methods disclosed herein for bypassing an existing graft and for improving the patency of an existing bypass graft can be used in combination, or in the alternative.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1

is a cross-sectional view of a human heart, showing a saphenous vein graft used to bypass a blockage in the coronary artery.





FIG. 2

is a cross-sectional view of a conduit placed in the myocardium to provide for the flow of oxygenated blood directly from the left ventricle in the heart into the coronary artery, bypassing the blockages in the coronary artery and the saphenous vein graft.





FIGS. 3A-C

are enlarged views illustrating the delivery of the conduit through the saphenous vein graft and into the myocardium.





FIGS. 4A-E

are enlarged views illustrating the delivery of a new vein lining into an existing vein graft used to bypass a blockage in the coronary artery.











DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT




As is well known, the coronary artery branches off the aorta and is positioned along the external surface of the heart wall. Oxygenated blood flows from the heart to the aorta, and on to the rest of the body, some of the blood flowing into the coronary artery. In some individuals, plaque builds up within the coronary artery, blocking the free flow of blood and causing complications ranging from mild angina to heart attack and death.




In order to restore the flow of oxygenated blood through the coronary artery, bypass surgery is performed. One or more venous segments are used to join the aorta and a site in the coronary artery distal to the blockage. The inserted vascular segments act to bypass the blocked portion of the coronary artery and thus provide for a free or unobstructed flow of oxygenated blood from the heart. To perform the bypass, an incision is made through the patient's sternum (sternotomy), and the patient is placed on a bypass pump so that the heart and surrounding vessels can be operated on while not beating. Typically, a saphenous vein graft is harvested from the patient's leg, and the bypass graft is anastomosed to the aorta and to the coronary artery. It should be understood, however, that other arterial or venous segments may be used to perform the bypass and that other blocked vessels may be bypassed. The term “vascular graft” as used herein refers to any such venous or arterial segment used in any bypass procedure.





FIG. 1

illustrates a human heart having a saphenous vein graft VG attached to the aorta AO and to the coronary artery CA at a site distal to the blockage BL in the coronary artery CA. As noted above, over time, the vein graft VG itself may become diseased, stenosed, or occluded, and intervention is necessary to once again restore the flow of oxygenated blood through the coronary artery CA.





FIG. 2

illustrates means for bypassing the blockage BL in the coronary artery, as well as in the vein graft VG. A conduit


10


is positioned in the heart wall or myocardium MYO. Although the bypass described herein is from the left ventricle of the heart to the coronary artery, it should be understood that this is merely exemplary. The principles of the present invention are not limited to left ventricular conduits, and include conduits for communicating bodily fluids from any space within a patient to another space within a patient, including any mammal. Furthermore, such fluid communication through the conduits is not limited to any particular direction of flow and can be antegrade or retrograde with respect to the normal flow of fluid. Moreover, the conduits may communicate between a bodily space and a vessel or from one vessel to another vessel (such as an artery to a vein or vice versa). Moreover, the conduits can reside in a single bodily space so as to communicate fluids from one portion of the space to another. For example, the conduits can be used to achieve a bypass within a single vessel, such as communicating blood from a proximal portion of an occluded coronary artery to a more distal portion of that same coronary artery.




In addition, the conduits and related methods can preferably traverse various intermediate destinations and are not limited to any particular flow sequence. For example, in one preferred embodiment of the present invention, the conduit communicates from the left ventricle, through the myocardium, into the pericardial space, and then into the coronary artery. However, other preferred embodiments are disclosed, including direct transmyocardial communication from a left ventricle, through the myocardium and into the coronary artery. Thus, as emphasized above, the term “transmyocardial” should not be narrowly construed in connection with the preferred fluid communication conduits, and other non-myocardial and even non-cardiac fluid communication are preferred as well. With respect to the walls of the heart (and more specifically the term “heart wall”), the preferred conduits and related methods are capable of fluid communication through all such walls including, without limitation, the pericardium, epicardium, myocardium, endocardium, septum, etc.




The bypass which is achieved with certain preferred embodiments and related methods is not limited to a complete bypass of bodily fluid flow, but can also include a partial bypass which advantageously supplements the normal bodily blood flow. Moreover, the occlusions which are bypassed may be of a partial or complete nature, and therefore the terminology “bypass” or “occlusion” should not be construed to be limited to a complete bypass or a complete occlusion but can include partial bypass and partial occlusion as described.




The preferred conduits and related methods disclosed herein can also provide complete passages or partial passages through bodily tissues. In this regard, the conduits can comprise stents, shunts, or the like, and therefore provide a passageway or opening for bodily fluid such as blood. Moreover, the conduits are not necessarily stented or lined with a device but can comprise mere tunnels or openings formed in the tissues of the patient.




The conduits of the present invention preferably comprise both integral or one-piece conduits as well as plural sections joined together to form a continuous conduit. The present conduits can be deployed in a variety of methods consistent with sound medical practice including vascular or surgical deliveries, including minimally invasive techniques. For example, various preferred embodiments of delivery rods and associated methods may be used. In one embodiment, the delivery rod is solid and trocar-like. It may be rigid or semi-rigid and capable of penetrating the tissues of the patient and thereby form the conduit, in whole or in part, for purposes of fluid communication. In other preferred embodiments, the delivery rods may be hollow so as to form the conduits themselves (e.g., the conduits are preferably self-implanting or self-inserting) or have a conduit mounted thereon (e.g., the delivery rod is preferably withdrawn leaving the conduit installed). Thus, the preferred conduit device and method for installation is preferably determined by appropriate patient indications in accordance with sound medical practices.




The conduit


10


, as illustrated in

FIG. 2

, preferably extends from the left ventricle LV of the heart to the coronary artery CA at a site that is distal to the site of the blockage BL. The conduit


10


is preferably made of a biocompatible material such as titanium, titanium alloys, nickel alloys, or biocompatible polymer. If desired, the conduit


10


can incorporate a valve that allows blood to flow freely from the left ventricle LV to the coronary artery CA but prevents the backflow of blood from the coronary artery


10


to the heart. Further details regarding conduits and conduit delivery systems are described in related patent applications: U.S. application Ser. No. 09/368,868, filed Aug. 4, 1999, entitled DELIVERY METHODS FOR LEFT VENTRICULAR CONDUIT, U.S. application Ser. No. 09/369,048, filed Aug. 4, 1999, entitled DESIGNS FOR LEFT VENTRICULAR CONDUIT, U.S. application Ser. No. 09/369,061, filed Aug. 4, 1999, entitled LEFT VENTRICULAR CONDUIT WITH BLOOD VESSEL GRAFT, U.S. application Ser. No. 09/368,393, filed Aug. 4, 1999, entitled VALVE DESIGNS FOR LEFT VENTRICULAR CONDUIT, U.S. application Ser. No. 09/369,039, filed Aug. 4, 1999, entitled LEFT VENTRICULAR CONDUITS TO CORONARY ARTERIES AND METHODS FOR CORONARY BYPASS, and U.S. application Ser. No. 09/368,644, filed Aug. 4, 1999, entitled BLOOD FLOW CONDUIT DELVIERY SYSTEM AND METHOD OF USE, and U.S. Pat. Nos. 5,429,144, and 5,662,124, the disclosures of which are all hereby incorporated by reference in their entirety.




In order to bypass the blockages in both the coronary artery CA and the vein graft VG, thereby providing for enhanced blood flow in the patient, the conduit


10


must be positioned at a site which is downstream or distal to the blockage BL in the coronary artery CA and the attachment site of the vein graft VG to the coronary artery CA. This allows oxygenated blood to flow directly from the left ventricle LV of the heart into the coronary artery CA and on to the rest of the body without encountering the blockage BL and without having to travel through the blocked vein graft VG. Although some proximal flow may occur through the vein graft, it is advantageous to place the conduit in a position which completely bypasses the blockage(s). The preferred positioning of the conduit


10


is illustrated in FIG.


2


.





FIGS. 3A-3C

depict a preferred method for delivery of the conduit


10


into the myocardium MYO. Although the figures illustrate the delivery of the conduit


10


percutaneously, it should be appreciated that the percutaneous approach is not essential to achieve many objects of the present invention, and therefore, an open-chest or other approach can also be used. In the preferred embodiment illustrated, the conduit


10


is delivered percutaneously, through the aorta AO and through the vein graft VG, thereby ensuring that both the original blockage BL in the coronary artery CA and the vein graft VG itself are bypassed. Other methods of delivery of the conduit


10


through the vein graft VG to a site in the myocardium MYO past both the blockage BL in the coronary artery CA and the site of attachment of the vein graft VG are also contemplated.




The conduit


10


is first mounted on the distal end of a steerable delivery catheter


12


(FIG.


3


A). The catheter


12


is delivered into the patient's vasculature, such as through the femoral artery in the thigh, and through the aorta AO until it reaches the site of attachment of the vein graft VG. The catheter


12


is then delivered through the vein graft VG and into the coronary artery CA. The distal end of the catheter


12


is positioned adjacent the desired insertion point in the myocardium MYO. The conduit


10


is then inserted into the myocardium MYO, such that one end of the conduit


10


is positioned in the left ventricle LV of the heart, and the other end is positioned in the coronary artery CA (FIG.


3


B). Methods of conduit delivery are described in detail in the above-referenced U.S. application Ser. No. 09/368,868, filed Aug. 4, 1999, entitled DELIVERY METHODS FOR LEFT VENTRICULAR CONDUIT, and in U.S. Pat. Nos. 5,429,144 and No. 5,409,019, all of which are hereby incorporated by reference in their entirety. The conduit


10


therefore provides for the shunting of oxygenated blood directly from the left ventricle LV of the heart into the coronary artery CA.




The conduit


10


can include anchoring means such as hooks, barbs, flanges or collars, or can be sutured, stapled or otherwise anchored in place to prevent conduit migration. The position of the conduit can be checked radiographically, and adjusted if necessary. As illustrated in

FIG. 3C

, after the conduit


10


has been properly positioned in the myocardium MYO, the delivery catheter


12


is withdrawn from the patient.




Another embodiment of the present invention is illustrated in

FIGS. 4A-D

. In this embodiment, an existing vascular graft is provided with a new, biocompatible lining, which allows for the free passage of blood therethrough. The lining can be formed of any biocompatible material, such as various polymers, but is preferably formed from a section of blood vessel, such as a vein, taken from the patient. The section of vein or other blood vessel harvested preferably contains one or more one-way valves, which occur naturally in the veins. In a preferred embodiment, the new vein section used to line the existing graft is obtained from the saphenous vein in the patient. Of course a blood vessel taken from a human or animal donor could also be used. For example, a fetal pig or piglet could be obtained and dissected to remove a section of the pulmonary artery having a pulmonic valve therein, or a section of the aorta having an aortic valve, or any other similar vessel having a naturally occurring valve system.




The vein section harvested is preferably sized so as to be approximately the same length as the original vein graft VG, but other lengths are also contemplated. The natural vein is biocompatible and therefore reduces the occurrence of problems associated with rejection and clotting. In addition, the vein section provides a natural valve system that is already in use throughout the body to prevent the backflow of blood. After the vein section has been harvested, it is mounted on the distal end of a catheter for insertion into the patient, as described below.




Turning now to

FIG. 4A

, there is illustrated a steerable delivery catheter


20


having an inner lumen. A vein section


22


obtained as described above is mounted on the distal end of a second catheter


24


, which is inserted through the lumen of the delivery catheter


20


. The second catheter


24


preferably has an inflatable balloon


26


mounted on its distal end, over which the vein section


22


is concentrically mounted. Inflatable catheters are well known to these of skill in the art, and can be readily obtained from various commercial sources. The delivery catheter


20


and second catheter


24


are preferably delivered together into the patient's vasculature, such as through the femoral artery in the thigh, and through the aorta AO until they reach the site of attachment of the vein graft VG. The second catheter


24


bearing the vein section


22


is then delivered through the vein graft VG, as illustrated in FIG.


4


B.




After the new vein section


22


, mounted on the distal end of the second catheter


24


, is delivered into the vein graft VG, the delivery catheter


20


is withdrawn, as illustrated in FIG.


4


C. The second catheter


24


and new vein section


22


remain in position inside the vein graft VG. The balloon


26


at the distal end of the second catheter


24


is inflated as shown in FIG.


4


D. Expansion of the balloon


26


forces the new vein section


22


against the interior of the existing vein graft VG, expanding the interior lumen in both the existing graft VG and the new vein section


22


, opening a new passage for blood to flow through the vein graft VG. The balloon


26


is deflated, and the second catheter


24


is withdrawn from the patient, leaving the existing vein graft VG with a new vein lining, as illustrated in FIG.


4


E.




Preferably, the new vein section


22


is attached to the existing vein graft VG or to the aorta AO at one end and to the coronary artery CA at the other end. The new vein section


22


can be attached by sutures, staples, or other attachment means.




The embodiments illustrated and described above are provided merely as examples of certain preferred embodiments of the present invention. Changes and modifications can be made to the embodiments presented herein by those skilled in the art without departure from the spirit and scope of the invention, as defined by the claims which follow.



Claims
  • 1. A method for placing a conduit in a heart wall between a heart chamber and a coronary vessel, comprising:providing a conduit on a distal end of a delivery catheter; advancing the delivery catheter and the conduit through a bypass graft; inserting the conduit in the heart wall between the heart chamber and the coronary vessel at a location proximate a site of attachment of the bypass graft; and anchoring the conduit in position within the heart wall.
  • 2. The method of claim 1, wherein the coronary vessel is a coronary artery.
  • 3. The method of claim 2, further comprising advancing the delivery catheter and the conduit from an aorta through the bypass graft and into the coronary artery.
  • 4. The method of claim 3, further comprising advancing the conduit substantially transverse to the coronary artery.
  • 5. The method of claim 1, wherein the bypass graft is a coronary artery bypass graft.
  • 6. The method of claim 1, further comprising advancing the delivery catheter and the conduit percutaneously through the bypass graft.
  • 7. The method of claim 1, wherein inserting the conduit comprises inserting the conduit in the heart wall such that blood flows directly from the heart chamber to the coronary vessel and bypasses the bypass graft.
  • 8. The method of claim 1, wherein the conduit is chosen from a stent and a shunt.
  • 9. The method of claim 1, wherein inserting the conduit includes inserting the conduit such that it opens at one end into the heart chamber and at an opposite end into the coronary vessel.
  • 10. The method of claim 9, wherein inserting the conduit includes inserting the conduit between a left ventricle and a coronary artery.
  • 11. The method of claim 1, further comprising removing the delivery catheter after the conduit has been placed in the heart wall.
  • 12. The method of claim 1, further comprising providing the conduit with an anchoring mechanism chosen from hooks, barbs, flanges, and collars to anchor the conduit into position in the heart wall.
  • 13. The method of claim 1, wherein anchoring the conduit includes suturing the conduit into position.
  • 14. The method of claim 1, wherein the chamber is the left ventricle.
  • 15. The method of claim 1, further comprising visualizing the position of the conduit in the heart wall during the insertion of the conduit.
  • 16. The method of claim 15, wherein visualizing the position of the passage includes visualizing the position radiographically.
  • 17. The method of claim 1, wherein anchoring the conduit includes stapling the conduit into position.
Parent Case Info

This is a continuation of U.S. application Ser. No. 09/368,483, filed Aug. 4, 1999, now U.S. Pat. No. 6,253,768, which is incorporated herein by reference.

US Referenced Citations (163)
Number Name Date Kind
4086665 Poirier May 1978 A
4503568 Madras Mar 1985 A
4546499 Possis et al. Oct 1985 A
4562597 Possis et al. Jan 1986 A
4733665 Palmaz Mar 1988 A
4769029 Patel Sep 1988 A
5135467 Citron Aug 1992 A
5193546 Shaknovich Mar 1993 A
5258008 Wilk Nov 1993 A
5287861 Wilk Feb 1994 A
5330486 Wilk Jul 1994 A
5409019 Wilk Apr 1995 A
5429144 Wilk Jul 1995 A
5443497 Venbrux Aug 1995 A
5456712 Maginot Oct 1995 A
5456714 Owen Oct 1995 A
5470320 Tifenbrun et al. Nov 1995 A
5571167 Maginot Nov 1996 A
5655548 Nelson et al. Aug 1997 A
5662124 Wilk Sep 1997 A
5676670 Kim Oct 1997 A
5695504 Gifford, III et al. Dec 1997 A
5702412 Popov et al. Dec 1997 A
5746709 Rom et al. May 1998 A
5755682 Knudson et al. May 1998 A
5758663 Wilk et al. Jun 1998 A
5797920 Kim Aug 1998 A
5797933 Snow et al. Aug 1998 A
5797946 Chin Aug 1998 A
5800522 Campbell et al. Sep 1998 A
5810836 Hussein et al. Sep 1998 A
5817113 Gifford, III et al. Oct 1998 A
5824071 Nelson et al. Oct 1998 A
5830222 Makower Nov 1998 A
5865723 Love Feb 1999 A
5875782 Ferrari et al. Mar 1999 A
5876419 Carpenter et al. Mar 1999 A
5878751 Hussein et al. Mar 1999 A
5893848 Negus et al. Apr 1999 A
5904697 Gifford, III et al. May 1999 A
5908028 Wilk Jun 1999 A
5908029 Knudson et al. Jun 1999 A
5922022 Nash et al. Jul 1999 A
5931842 Goldsteen et al. Aug 1999 A
5935119 Guy et al. Aug 1999 A
5944019 Knudson et al. Aug 1999 A
5971993 Hussein et al. Oct 1999 A
5976159 Bolduc et al. Nov 1999 A
5976178 Goldsteen et al. Nov 1999 A
5976192 McIntyre et al. Nov 1999 A
5980548 Evans et al. Nov 1999 A
5984955 Wisselink Nov 1999 A
5984956 Tweden et al. Nov 1999 A
5989276 Houser et al. Nov 1999 A
5989287 Yang et al. Nov 1999 A
5993468 Rygaard Nov 1999 A
6007544 Kim Dec 1999 A
6007576 McClellan Dec 1999 A
6026814 LaFontaine et al. Feb 2000 A
6027497 Daniel et al. Feb 2000 A
6029672 Vanney et al. Feb 2000 A
6035856 LaFontaine et al. Mar 2000 A
6042581 Ryan et al. Mar 2000 A
6045565 Ellis et al. Apr 2000 A
6053911 Ryan et al. Apr 2000 A
6053924 Hussein Apr 2000 A
6053942 Eno et al. Apr 2000 A
6056743 Ellis et al. May 2000 A
6063082 DeVore et al. May 2000 A
6067988 Mueller May 2000 A
6068638 Makower May 2000 A
6071292 Makower et al. Jun 2000 A
6076529 Vanney et al. Jun 2000 A
6080163 Hussein et al. Jun 2000 A
6092526 LaFontaine et al. Jul 2000 A
6093166 Knudson et al. Jul 2000 A
6102941 Tweden et al. Aug 2000 A
6106538 Shiber Aug 2000 A
6113630 Vanney et al. Sep 2000 A
6113823 Eno Sep 2000 A
6123682 Knudson et al. Sep 2000 A
6126649 VanTassel et al. Oct 2000 A
6139541 Vanney et al. Oct 2000 A
6155264 Ressemann et al. Dec 2000 A
6159225 Makower Dec 2000 A
6165188 Saadat et al. Dec 2000 A
6182668 Tweden et al. Feb 2001 B1
6186972 Nelson et al. Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6193726 Vanney Feb 2001 B1
6196230 Hall et al. Mar 2001 B1
6197050 Eno et al. Mar 2001 B1
6200310 Ben-Haim et al. Mar 2001 B1
6213126 LaFontaine et al. Apr 2001 B1
6214041 Tweden et al. Apr 2001 B1
6217575 DeVore et al. Apr 2001 B1
6223752 Vanney et al. May 2001 B1
6231587 Makower May 2001 B1
6237607 Vanney et al. May 2001 B1
6238406 Ellis et al. May 2001 B1
6250305 Tweden Jun 2001 B1
6253768 Wilk Jul 2001 B1
6253769 LaFontaine et al. Jul 2001 B1
6254564 Wilk et al. Jul 2001 B1
6258119 Hussein et al. Jul 2001 B1
6261304 Hall et al. Jul 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6283983 Makower et al. Sep 2001 B1
6287317 Makower et al. Sep 2001 B1
6290728 Phelps et al. Sep 2001 B1
6302875 Makower et al. Oct 2001 B1
6302892 Wilk Oct 2001 B1
6330884 Kim Dec 2001 B1
6350248 Knudson et al. Feb 2002 B1
6361519 Knudson et al. Mar 2002 B1
6363939 Wilk Apr 2002 B1
6375615 Flaherty et al. Apr 2002 B1
6379319 Garibotto et al. Apr 2002 B1
6387119 Wolf et al. May 2002 B2
6390098 LaFontaine et al. May 2002 B1
6406488 Tweden et al. Jun 2002 B1
6406491 Vanney Jun 2002 B1
6409697 Eno et al. Jun 2002 B2
6409751 Hall et al. Jun 2002 B1
6432127 Kim et al. Aug 2002 B1
6443158 LaFontaine et al. Sep 2002 B1
6447539 Nelson et al. Sep 2002 B1
6454704 Knudson et al. Sep 2002 B1
6454760 Vanney Sep 2002 B2
6458323 Boekstegers Oct 2002 B1
20010002948 Vanney Jun 2001 A1
20010004699 Gittings et al. Jun 2001 A1
20010016700 Eno et al. Aug 2001 A1
20010025643 Foley Oct 2001 A1
20010027287 Shmulewitz et al. Oct 2001 A1
20010034547 Hall et al. Oct 2001 A1
20010037149 Wilk Nov 2001 A1
20010039426 Makower et al. Nov 2001 A1
20010039445 Hall et al. Nov 2001 A1
20010041902 Lepulu et al. Nov 2001 A1
20010047165 Makower et al. Nov 2001 A1
20010053932 Phelps et al. Dec 2001 A1
20020002349 Flaherty et al. Jan 2002 A1
20020004662 Wilk Jan 2002 A1
20020004663 Gittings et al. Jan 2002 A1
20020007138 Wilk et al. Jan 2002 A1
20020029079 Kim et al. Mar 2002 A1
20020049486 Knudson et al. Apr 2002 A1
20020052637 Houser et al. May 2002 A1
20020058897 Renati May 2002 A1
20020062146 Makower et al. May 2002 A1
20020065478 Knudson et al. May 2002 A1
20020072699 Knudson et al. Jun 2002 A1
20020077566 Laroya et al. Jun 2002 A1
20020092535 Wilk Jul 2002 A1
20020095111 Tweden et al. Jul 2002 A1
20020100484 Hall et al. Aug 2002 A1
20020111672 Kim et al. Aug 2002 A1
20020123698 Garibotto et al. Sep 2002 A1
20020144696 Sharkawy et al. Oct 2002 A1
20020161424 Rapacki et al. Oct 2002 A1
20020165479 Wilk Nov 2002 A1
20020165606 Wolf et al. Nov 2002 A1
Foreign Referenced Citations (89)
Number Date Country
0 876 803 Nov 1998 EP
1 097 676 May 2001 EP
1 166 721 Jan 2002 EP
2 316 322 Feb 1998 GB
WO 9625886 Aug 1996 WO
9713463 Apr 1997 WO
9713471 Apr 1997 WO
9727893 Aug 1997 WO
9727897 Aug 1997 WO
9727898 Aug 1997 WO
WO 9731590 Sep 1997 WO
9732551 Sep 1997 WO
9743961 Nov 1997 WO
9802099 Jan 1998 WO
WO 9803118 Jan 1998 WO
9808456 Mar 1998 WO
9810714 Mar 1998 WO
9816161 Apr 1998 WO
9819607 May 1998 WO
WO 9838939 Sep 1998 WO
9838941 Sep 1998 WO
WO 9838942 Sep 1998 WO
9844869 Oct 1998 WO
9846115 Oct 1998 WO
9846119 Oct 1998 WO
9849963 Nov 1998 WO
9849964 Nov 1998 WO
9853759 Dec 1998 WO
9855027 Dec 1998 WO
9857590 Dec 1998 WO
9857591 Dec 1998 WO
WO 9857592 Dec 1998 WO
9806356 Feb 1999 WO
WO 9908603 Feb 1999 WO
9908624 Feb 1999 WO
9949793 Mar 1999 WO
9917683 Apr 1999 WO
9921490 May 1999 WO
9921510 May 1999 WO
9922655 May 1999 WO
9925273 May 1999 WO
WO 9935979 Jul 1999 WO
9936000 Jul 1999 WO
9936001 Jul 1999 WO
WO 9937218 Jul 1999 WO
9938459 Aug 1999 WO
9940868 Aug 1999 WO
9947071 Sep 1999 WO
WO 9948427 Sep 1999 WO
9948545 Sep 1999 WO
9949790 Oct 1999 WO
9949910 Oct 1999 WO
9951162 Oct 1999 WO
WO 9952475 Oct 1999 WO
9953863 Oct 1999 WO
9960941 Dec 1999 WO
9962430 Dec 1999 WO
0009195 Feb 2000 WO
0012029 Mar 2000 WO
0015146 Mar 2000 WO
0015147 Mar 2000 WO
0015148 Mar 2000 WO
0015149 Mar 2000 WO
0015275 Mar 2000 WO
0018302 Apr 2000 WO
0021436 Apr 2000 WO
0021461 Apr 2000 WO
0021463 Apr 2000 WO
0024449 May 2000 WO
0033725 Jun 2000 WO
0041632 Jul 2000 WO
0041633 Jul 2000 WO
0045711 Aug 2000 WO
WO 0045886 Aug 2000 WO
0049954 Aug 2000 WO
0049956 Aug 2000 WO
0056387 Sep 2000 WO
0057814 Oct 2000 WO
0066007 Nov 2000 WO
0066009 Nov 2000 WO
0066035 Nov 2000 WO
0071195 Nov 2000 WO
WO 0110340 Feb 2001 WO
WO 0110341 Feb 2001 WO
WO 0110347 Feb 2001 WO
WO 0110348 Feb 2001 WO
WO 0110349 Feb 2001 WO
0117440 Mar 2001 WO
WO 0149187 Jul 2001 WO
Non-Patent Literature Citations (14)
Entry
Gardner, M.D. et al., “An Experimental Anatomic Study of Indirect Myocardial Revascularization,” Journal of Surgical Research, May 1971, vol. 11, No. 5, pp. 243-247.
Palmaz et al., “Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog,” AJR, 1985, vol. 145, pp. 821-825.
Palmaz et al., “Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertension,” AJR, 1986, vol. 147, pp. 1251-1254.
Richter, M.D. et al., “Transjugular Intrahepatic Portacaval Stent-Shunt: Preliminary Clinical Results,” Radiology, 1990, vol. 174, No. 3, pp. 1027-1030.
Zemel, M.D. et al., “Percutaneous Transjugular Portosystemic Shunt,” JAMA, 1991, vol. 266, No. 3, pp. 390-393.
Massimo, M.D. et al., “Myocardial Revascularization by a New Method of Carrying Blood Directly from the Left Ventricular Cavity into the Coronary Circulation,” Journal of Thoracic Surgeons, Aug. 1997, vol. 34, No. 2, pp. 257-264.
Lary, M.D. et al., “Myocardial Revascularization Experiments Using the Epicardium,” Archives of Surgery, Jan. 1969, vol. 98, No. 1, pp. 69-72.
Munro, M.D. et al., “The possibility of myocardial revascularization by creation of a left ventriculocoronary artery fistula,” Journal of Thoracic and Cardiovascular Surgery, Jul. 1969, vol. 58, No. 1, pp. 25-32.
Kuzela, M.D. et al., “Experimental evaluation fo direct transventricular revascularization,” The Journal of Thoracic and Cardiovascular Surgery, Jun. 1969, vol. 57, No. 6, pp. 770-773.
Lary et al., “A method for creating a coronary-myocardial arter,” Surgery, vol. 59, No. 6, Jun. 1966, pp. 1061-1064.
Anabtawi, M.D. et al., “Experimental evaluation of myocardial tunnelization as a method of myocardial revascularization,” The Journal of Thoracic and Cardiovascular Surgery, Nov. 1969, pp. 638-646.
Urschel, Jr., M.D., et al., “Direct and indirect myocardial revascularization: Follow-up and appraisal.” Surgery, vol. 6, No. 6, Dec. 1970, pp. 1087-1100.
Young, Jr. M.D., et al., “Preoperative Assessment of Left Ventricular Function in Patients Selected for Direct Myocardial Revascularization,” The Annals of Thoracic Surgery, vol. 11, No. 5, May 1971, pp. 695-402.
Tweden et al., “Ventriculocoronary Artery Bypass (VCAB), a Novel Approach to Myocardial Revascularization,” #2000-4653, Feb. 2000.
Continuations (1)
Number Date Country
Parent 09/368483 Aug 1999 US
Child 09/828793 US